Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Editas Medicine Q3 EPS $(0.55) Beats $(0.57) Estimate, Sales $5.34M Beat $3.42M Estimate

Author: Benzinga Newsdesk | November 03, 2023 07:02am
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.57) by 3.51 percent. This is a 32.1 percent increase over losses of $(0.81) per share from the same period last year. The company reported quarterly sales of $5.34 million which beat the analyst consensus estimate of $3.42 million by 56.02 percent. This is a 12.60K percent increase over sales of $42.00 thousand the same period last year.

Posted In: EDIT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist